RT Journal Article
T1 Impact of individualized management of breakthrough cancer pain on quality of life in advanced cancer patients: CAVIDIOPAL study.
A1 Tuca Rodríguez, Albert
A1 Núñez Viejo, Miguel
A1 Maradey, Pablo
A1 Canal-Sotelo, Jaume
A1 Guardia Mancilla, Plácido
A1 Gutiérrez Rivero, Sonia
A1 Raja Casillas, Inmaculada
A1 Herrera Abián, María
A1 López Bermudo, Cristina
K1 Breakthrough cancer pain
K1 Individualized therapy
K1 Palliative care
K1 Quality of life
K1 Transmucosal fentanyl
AB The main aim of the study was to assess the impact of individualized management of breakthrough cancer pain (BTcP) on quality of life (QoL) of patients with advanced cancer in clinical practice. A prospective, observational, multicenter study was conducted in patients with advanced cancer that were assisted by palliative care units. QoL was assessed with the EORTC QLQ-C30 questionnaire at baseline (V0) and after 28 days (V28) of individualized BTcP therapy. Data on background pain, BTcP, comorbidities, and frailty were also recorded. Ninety-three patients completed the study. Intensity, duration, and number of BTcP episodes were reduced (p  Individualized BTcP therapy improved QoL of patients with advanced cancer. Transmucosal fentanyl at low doses was the most used drug. This study was registered at ClinicalTrials.gov database (NCT02840500) on July 19, 2016.
YR 2021
FD 2021-02-03
LK http://hdl.handle.net/10668/17091
UL http://hdl.handle.net/10668/17091
LA en
DS RISalud
RD Apr 13, 2025